# US 2008/0188411 A1 · Reducing Myelin-Mediated Inhibition of Axon Regeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188411 A1
- Document ID: US20080188411A1
- Status: Published application
- Kind: A1
- Application number: 11/958,632
- Filed: 2007-12-18
- Published: 2008-08-07
- Earliest claimed: 2001-12-03
- Assignees: Children's Medical Center Corporation
- Inventors: Zhigang He; Kevin C. Wang; Vuk Koprivica; Jieun A. Kim
- Web page: https://patentgrep.com/patent/US20080188411A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 38/1787: {for neuromediators, e.g. serotonin receptor, dopamine receptor}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/55: Fab or Fab'
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Oligodendrocyte-myelin glycoprotein (OMgp)-specific binding agents are used to reduce OMgp-mediated axon growth inhibition. Mixtures of axons and OMgp and mixtures of Nogo receptor (NgR) and OMgp are used in pharmaceutical screens to characterize agents as inhibiting binding of NgR to OMgp and promoting axon regeneration.

## Claims

### Claim 1

A method for reducing axon growth inhibition mediated by OMgp in the central nervous system and detecting resultant reduced axon growth inhibition, the method comprising steps:
contacting a mixture comprising an axon and OMgp with an exogenous OMgp-specific binding agent and under conditions wherein the agent binds the OMgp and but for the presence of the agent, the axon is subject to growth inhibition mediated by the OMgp, and
detecting resultant reduced axon growth inhibition, wherein said agent comprises a soluble NgR peptide sufficient to specifically bind the OMgp and competitively inhibit binding of the OMgp to the NgR.

### Claim 2

A method for characterizing an agent as inhibiting binding of NgR to OMgp, the method comprising the steps of:
incubating a mixture comprising NgR, OMgp and an agent under conditions whereby but for the presence of the agent, the NgR and OMgp exhibit a control binding; and
detecting a reduced binding of the NgR to the OMgp, indicating that the agent inhibits binding of the NgR to the OMgp.

### Claim 3 (depends on 2)

A method according to claim 2, wherein at least one of the NgR and OMgp is soluble and GPI-cleaved.

### Claim 4 (depends on 2)

A method according to claim 2, wherein one of the NgR and OMgp is soluble and GPI-cleaved and the other is membrane-bound.

### Claim 5 (depends on 2)

A method according to claim 2, wherein at least one of the NgR and OMgp is recombinantly expressed on a surface of a cell.

### Claim 6

A pharmaceutical composition comprising a soluble NgR peptide and a pharmaceutically acceptable excipient, formulated in unit dosage sufficient to specifically bind OMgp and competitively inhibit binding of the OMgp to NgR, wherein the peptide consists of one of SEQ ID NOS: 1-6, or truncation thereof at least six residues in length.

### Claim 7 (depends on 6)

A composition according to claim 6, wherein the truncation is at least 16 residues in length.

### Claim 8 (depends on 6)

A composition according to claim 6, wherein the peptide consists of one of SEQ ID NOS: 1-6.

### Claim 9 (depends on 6)

A composition according to claim 6, wherein the peptide consists of SEQ ID NO: 1.

### Claim 10 (depends on 6)

A composition according to claim 6, wherein the peptide consists of SEQ ID NO: 1, and the truncation is at least 16 residues in length.
